Synteract Acquires Pediatric CRO KinderPharm
Synteract, a CRO, has acquired KinderPharm, a pediatric CRO, focused on advancing pediatric drug development across all phases of clinical research. Together, Synteract and KinderPharm will deliver a single source model for preclinical and clinical development, along with the operational and logistical understanding required in working with children and their families.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025